<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Arch Public Health</journal-id><journal-title-group><journal-title>Archives of Public Health</journal-title></journal-title-group><issn pub-type="ppub">0778-7367</issn><issn pub-type="epub">2049-3258</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4582342</article-id><article-id pub-id-type="publisher-id">2049-3258-73-S1-P5</article-id><article-id pub-id-type="doi">10.1186/2049-3258-73-S1-P5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Phase III randomised chemoprevention study of Selenium on the recurrence of non-invasive bladder cancer. The SELEnium and BLAdder cancer Trial (SELEBLAT)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Goossens</surname><given-names>Maria (Mieke)</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Zeegers</surname><given-names>Maurice</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Van Poppel</surname><given-names>Hendrik</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Joniau</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Ackaert</surname><given-names>Koen</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Ameye</surname><given-names>Filip</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Billiet</surname><given-names>Ignace</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Dillen</surname><given-names>Kurt</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Goeman</surname><given-names>Lieven</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Van Bruwaene</surname><given-names>Siska</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Van der Aa</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Vekemans</surname><given-names>Kris</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Buntinx</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>KU Leuven, Leuven, Belgium</aff><aff id="I2"><label>2</label>University Maastricht, Maastricht, Netherlands</aff><aff id="I3"><label>3</label>UZ Leuven, Leuven, Belgium</aff><aff id="I4"><label>4</label>Uz Leuven, Leuven, Belgium</aff><aff id="I5"><label>5</label>Sint-Elisabethziekenhuis, Turnhout, Belgium</aff><aff id="I6"><label>6</label>AZ Maria Middelares, Gent, Belgium</aff><aff id="I7"><label>7</label>AZ Groeninge, Kortrijk, Belgium</aff><aff id="I8"><label>8</label>Jessa ziekenhuis, Hasselt, Belgium</aff><aff id="I9"><label>9</label>H. Hart ziekenhuis, Roeselaere, Belgium</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2015</year></pub-date><volume>73</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Methods in Epidemiology Symposium</named-content><named-content content-type="supplement-sponsor">Publication of this supplement has been funded by KU Leuven.</named-content></supplement><fpage>P5</fpage><lpage>P5</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Goossens et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Goossens et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.archpublichealth.com/content/73/S1/P5"/><conference><conf-date><day>17</day><month>9</month><year>2015</year></conf-date><conf-name>Methods in Epidemiology Symposium</conf-name><conf-loc>Leuven, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8 %). The per-patient lifetime cost is the highest of all other types of cancer. Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder cancer. We therefore hypothesized that selenium may also be suitable for chemoprevention of recurrence.</p></sec><sec><title>Design</title><p>The SELEnium and BLAdder cancer Trial (SELEBLAT) was an academic phase III placebo-controlled, double-blind, randomized trial designed to determine the effect of selenium on recurrence of bladder cancer.</p></sec><sec sec-type="methods"><title>Method</title><p>The SELEBLAT study included 277 patients with non-invasive transitional cell carcinoma of the bladder on TURB operation in 16 Belgian hospitals. Patients were randomly assigned to selenium yeast (200 mg/day) supplementation for 3 years or matching placebo, in addition to standard care. All study personnel and participants were blinded to treatment assignment for the duration of the study.</p></sec><sec sec-type="results"><title>Results</title><p>After an average of 27 months 56 patients, 34 and 22 in treatment group one and two respectively, recurrenced. The Cox regression analysis showed no difference in recurrence-free interval between the two groups (HR = 0.75 (0.44 - 1.28)). Eight patients had progression from a low grade lesion to high grade lesion (HR = 1.89 (95% CI 0.45-7.90)).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Selenium yeast, in addition to standard care, did not diminish recurrence in bladder cancer patients. Based on the result of the Seleblat study, we do not recommend prescribing selenium to patients in order to prevent recurrence of bladder cancer. Our final results will be pooled with the results of a similar trial in the United Kingdom. This analysis will have sufficient statistical power to be able to confirm or refute our current recommendations.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier: NCT00729287</p></sec></body></article>